Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 3

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 3
---
 financial statements; therefore, actual results could differ from those estimates.

Loss
per share

Loss
per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of shares
of common stock outstanding during the period. Diluted loss per share is based upon the weighted average number of shares of common stock
and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which
are included under the treasury stock method when dilutive.

    F-6

The
following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would
have been anti-dilutive for the periods presented (share data):

SCHEDULE OF ANTI-DILUTIVE SECURITIES  

    Weighted average 

    Three months ended  
    Six months ended 

    June 30  
    June 30 

    2025  
    2024  
    2025  
    2024 
  
    Outstanding stock options 
     102,569  
     86,451  
     102,842  
     84,575 
  
    Warrants 
     312,354  
     110,385  
     306,861  
     110,385 

Research
and development expenses

Research
and development expenses include costs directly attributable to the conduct of research and development programs, including the cost
of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research
and development activities, including clinical trials and professional services. All costs associated with research and development are
expensed as incurred.

The
Company accrues for expenses resulting from obligations under agreements with contract research organizations (“CROs”), contract
manufacturing organizations (“CMOs”), and other outside service providers for which payment flows do not match the periods
over which services or materials are provided to the Company. Accruals are recorded based on estimates of services received and efforts
expended pursuant to agreements with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted
amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers
as to the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO, or outside service provider,
the payments